CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: January 6, 2014
Result type: Reports
Project Number: SR0366-000
Product Line: Reimbursement Review

Generic Name: Aripiprazole

Brand Name: Abilify Maintena

Manufacturer: Otsuka Canada Pharmaceutical Inc. & Lundbeck Canada Inc.

Therapeutic Area: Schizophrenia

Indications: Schizophrenia

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: December 19, 2014

Recommendation Type: List with criteria/condition